Can the pharmaceutical industry reduce attrition rates?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Part of the attrition may be due to low animal-to-human translational success rates; the so-called “translational failure” [3].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [3]
In the citing paper
“Even so, late-stage attritions are still frequent [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Inhibition of the hERG channel can be an indicator of the APD prolongation and cardiotoxicity in early stages of drug development [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Less than 20 years ago, developing a drug took ~12 years, cost under a billion dollars, and the biggest challenges were failures due to efficacy or toxicity-induced attrition2.”
From Exploiting machine learning for end-to-end drug discovery and development (2019) · cites this paper as [2]
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265 · cited 1×
“In 2001, the costs of discovering and developing a drug were of the order of US d804 millio”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“We have, in a similar manner, provided very strong evidence that inhibition of β-secretase inhibits the production of amyloid-β in knockout mic”
ResultGowen, M., Lazner, F., Dodds, R., Kapadia, R., Feild, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tellis, I., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1654 · Cited by 490
Self-citationMa, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
Booth, B. L., Glassman, R. H., & Ma, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1158 · Cited by 84
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling
Lazner, F., Gowen, M., & Kola, I. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01563-4 · Cited by 18 · cited 1×
“and that cathepsin K is involved in bone resorption (further compelling proof of mechanism is provided by humans with pycnodysostosi”
BackgroundSelf-citation2003 approvals: a year of innovation and upward trends
Frantz, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1327 · Cited by 15
Research works printed but not linked: 4
- Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
- Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
- Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
- Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
Cited by
Items 301–400 of 1,025
Multiorgan Microphysiological Systems for Drug Development: Strategies, Advances, and Challenges
Wang, Y. I., Carmona, C., Hickman, J. J., & Shuler, M. L. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701000 · Cited by 167
Multiparameter In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using iPSC Cells
Sirenko, O., Crittenden, C., Callamaras, N., Hesley, J., Chen, Y.-W., Funes, C., Rusyn, I., Anson, B., & Cromwell, E. F. (2013) · SLAS Discovery · doi:10.1177/1087057112457590 · Cited by 170
“A primary cause of compound attrition in preclinical drug development is cardiotoxicity.(1) Early detection of cardiovascular side effects is critical to avoid late-stage preclinical termination, adverse cardiac-related events during clinical trials, or recall of a drug from the market.”
BackgroundBernardo, B. C., Ooi, J. Y. Y., Weeks, K. L., Patterson, N. L., & McMullen, J. R. (2018) · Physiological Reviews · doi:10.1152/physrev.00043.2016 · Cited by 160
Drug repurposing for breast cancer therapy: Old weapon for new battle
Aggarwal, S., Verma, S. S., Aggarwal, S., & Gupta, S. C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.012 · Cited by 163
“The overall success rate of development of new drugs (6%) and repositioning of drugs does not vary much as the ultimate efficacy remains same [150].”
BackgroundHigh-throughput organ-on-a-chip systems: Current status and remaining challenges
Probst, C., Schneider, S., & Loskill, P. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.02.004 · Cited by 171
Changing Trends in Computational Drug Repositioning
Yella, J. K., Yaddanapudi, S., Wang, Y., & Jegga, A. G. (2018) · Pharmaceuticals · doi:10.3390/ph11020057 · Cited by 166
“Nearly 62% of the compounds fail in Phase II and approximately 45% attrition occurs in Phase III [4].”
BackgroundFundamental aspects of DMPK optimization of targeted protein degraders
Cantrill, C., Chaturvedi, P., Rynn, C., Petrig Schaffland, J., Walter, I., & Wittwer, M. B. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.03.012 · Cited by 162
Drug Development: From Concept to Marketing!
Tamimi, N. A. M., & Ellis, P. (2009) · Nephron Clinical Practice · doi:10.1159/000232592 · Cited by 159
The Firm as an Engine of Imagination: Organizational prospection and the making of economic futures
Beckert, J. (2021) · Organization Theory · doi:10.1177/26317877211005773 · Cited by 199
“This is confirmed not only by the high failure rate of new ventures but also by the frequent failure of established firms to successfully develop and place new products in the market (Gourville, 2006; Kola & Landis, 2004).”
BackgroundEbbels, T. M. D., Keun, H. C., Beckonert, O. P., Bollard, M. E., Lindon, J. C., Holmes, E., & Nicholson, J. K. (2007) · Journal of Proteome Research · doi:10.1021/pr0703021 · Cited by 164
Nanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles
Wais, U., Jackson, A. W., He, T., & Zhang, H. (2016) · Nanoscale · doi:10.1039/c5nr07161e · Cited by 164
Naturally-Derived Biomaterials for Tissue Engineering Applications
Brovold, M., Almeida, J. I., Pla-Palacín, I., Sainz-Arnal, P., Sánchez-Romero, N., Rivas, J. J., Almeida, H., Dachary, P. R., Serrano-Aulló, T., Soker, S., et al. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-0947-2_23 · Cited by 160
Drug‐Target Residence Time—A Case for G Protein‐Coupled Receptors
Guo, D., Hillger, J. M., IJzerman, A. P., & Heitman, L. H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21307 · Cited by 166
Structure‐based Drug Metabolism Predictions for Drug Design
Sun, H., & Scott, D. O. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00899.x · Cited by 162
“An analysis of the first-in-human registration for ten big pharma companies demonstrated only a 10% total success rate leading to the final FDA approval (8).”
BackgroundArtificial intelligence in chemistry and drug design
Brown, N., Ertl, P., Lewis, R., Luksch, T., Reker, D., & Schneider, N. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00317-x · Cited by 165
Models for open innovation in the pharmaceutical industry
Schuhmacher, A., Germann, P., Trill, H., & Gassmann, O. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.013 · Cited by 165
Vandecruys, R., Peeters, J., Verreck, G., & Brewster, M. E. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.05.006 · Cited by 163
Next-Generation Treatments for Mental Disorders
Insel, T. R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004873 · Cited by 164
“With 80% of compounds failing in phase 2 (2) and 70% of preclinical target validation claims appearing nonreplicable (75) the f eld needs more rigor, with progress def ned by informative negative data as well as f ndings that promise a new therapeutic breakthrough.”
BackgroundLiterature Mining for the Discovery of Hidden Connections between Drugs, Genes and Diseases
Frijters, R., van Vugt, M., Smeets, R., van Schaik, R., de Vlieg, J., & Alkema, W. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000943 · Cited by 161
“Despite the strong increase in funding of research and development the last decade, the number of drugs that reach the market each year is lagging behind [71].”
Chu, V., Einolf, H. J., Evers, R., Kumar, G., Moore, D., Ripp, S., Silva, J., Sinha, V., Sinz, M., & Skerjanec, A. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027029 · Cited by 162
“…on a survey conducted in 2004, the major factors for compound attrition during clinical development are lack of efficacy, toxicity, and safety, and suboptimal pharmacokinetics and/or bioavailability, with the remaining failures due to financial and/or commercial reasons (Kola and Landis, 2004).”
BackgroundDissecting and rebuilding the glioblastoma microenvironment with engineered materials
Wolf, K. J., Chen, J., Coombes, J. D., Aghi, M. K., & Kumar, S. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0135-y · Cited by 158
Hartmann, M., & Hassan, A. (2006) · Research Policy · doi:10.1016/j.respol.2005.12.005 · Cited by 163
“However, between 1996 and 2001 only one new drug launch of this category was achieved on average (Bolten and DeGregorio, 2002), and this decline in productivity proceeds (Kola and Landis, 2004).”
BackgroundYang, S., & Kar, S. (2023) · Artificial Intelligence Chemistry · doi:10.1016/j.aichem.2023.100011 · Cited by 194
Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)96008-4 · Cited by 161
Mapping Adverse Drug Reactions in Chemical Space
Scheiber, J., Jenkins, J. L., Sukuru, S. C. K., Bender, A., Mikhailov, D., Milik, M., Azzaoui, K., Whitebread, S., Hamon, J., Urban, L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801546k · Cited by 160
Cardiovascular organ-on-a-chip platforms for drug discovery and development
Ribas, J., Sadeghi, H., Manbachi, A., Leijten, J., Brinegar, K., Zhang, Y. S., Ferreira, L., & Khademhosseini, A. (2016) · Applied In Vitro Toxicology · doi:10.1089/aivt.2016.0002 · Cited by 161
“Between 1991 and 2000, the rate of clinical trial success in cardiovascular drug development was as low as 20%.(11) Moreover, over the past five decades, adverse side effects have been a major reason for cardiovascular drugs being rejected or retracted from the market.”
BackgroundBeauchamp, P., Moritz, W., Kelm, J. M., Ullrich, N. D., Agarkova, I., Anson, B. D., Suter, T. M., & Zuppinger, C. (2015) · Tissue Engineering Part C: Methods · doi:10.1089/ten.tec.2014.0376 · Cited by 161
“The majority of drug attrition occurs in late stages of development when the costs incurred are already very high.(2) Therefore, there is a clear need for in vitro models that faithfully replicate the tissue environment.”
Present state and future perspectives of using pluripotent stem cells in toxicology research
Wobus, A. M., & Löser, P. (2011) · Archives of Toxicology · doi:10.1007/s00204-010-0641-6 · Cited by 159
Liver-Kidney-on-Chip To Study Toxicity of Drug Metabolites
Theobald, J., Ghanem, A., Wallisch, P., Banaeiyan, A. A., Andrade-Navarro, M. A., Taškova, K., Haltmeier, M., Kurtz, A., Becker, H., Reuter, S., et al. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00417 · Cited by 157
Preclinical development of molecular-targeted agents for cancer
Ocana, A., Pandiella, A., Siu, L. L., & Tannock, I. F. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.194 · Cited by 159
Yokoyama, Y., Sasaki, Y., Terasaki, N., Kawataki, T., Takekawa, K., Iwase, Y., Shimizu, T., Sanoh, S., & Ohta, S. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00913 · Cited by 160
Miller, R. R., Madeira, M., Wood, H. B., Geissler, W. M., Raab, C. E., & Martin, I. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01813 · Cited by 166
Constructing and Deconstructing Stem Cell Models of Neurological Disease
Han, S. S. W., Williams, L. A., & Eggan, K. C. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.003 · Cited by 159
“Nearly 90% of new drugs tested in humans fail to ultimately come to clinical approval, with central nervous system disorders as a therapeutic area, among those with the highest rate of attrition (Kola and Landis, 2004).”
The future of drug development: advancing clinical trial design
Orloff, J., Douglas, F., Pinheiro, J., Levinson, S., Branson, M., Chaturvedi, P., Ette, E., Gallo, P., Hirsch, G., Mehta, C., et al. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3025 · Cited by 158
Baillie, T. A. (2006) · Chemical Research in Toxicology · doi:10.1021/tx060062o · Cited by 160
Saravanakumar, A., Sadighi, A., Ryu, R. J., & Akhlaghi, F. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00750-8 · Cited by 165
Unger, C., Kramer, N., Walzl, A., Scherzer, M., Hengstschläger, M., & Dolznig, H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.015 · Cited by 158
Lennernäs, H. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.016 · Cited by 171
Human induced pluripotent stem cells and their use in drug discovery for toxicity testing
Scott, C. W., Peters, M. F., & Dragan, Y. P. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.02.020 · Cited by 171
Vrettos, E. I., Mező, G., & Tzakos, A. G. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.80 · Cited by 176
Anticancer Effects of Niclosamide in Human Glioblastoma
Wieland, A., Trageser, D., Gogolok, S., Reinartz, R., Höfer, H., Keller, M., Leinhaas, A., Schelle, R., Normann, S., Klaas, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2895 · Cited by 156
“Both strategies are burdened with high attrition rates during clinical translation (5, 6).”
BackgroundPhysicochemical drug properties associated with in vivo toxicological outcomes: a review
Price, D. A., Blagg, J., Jones, L., Greene, N., & Wager, T. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903042318 · Cited by 147
“The use of early in vivo toxicology testing to de-risk both pharmacology related and compound based toxicity is a commonly applied strategy in drug discovery [2,3] and strategies regarding screening paradigms are continually evolving [4].”
BackgroundMerging Systems Biology with Pharmacodynamics
Iyengar, R., Zhao, S., Chung, S.-W., Mager, D. E., & Gallo, J. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003563 · Cited by 156
Burden, N., Chapman, K. L., Sewell, F. R., & Robinson, V. (2015) · PubMed Central · Cited by 192
Löscher, W. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.05.016 · Cited by 164
Antibakterielle Naturstoffe in der medizinischen Chemie – Exodus oder Renaissance?
von Nussbaum, F., Brands, M., Hinzen, B., Weigand, S., & Häbich, D. (2006) · Angewandte Chemie · doi:10.1002/ange.200600350 · Cited by 173
More than 3Rs: The importance of scientific validity for harm-benefit analysis of animal research
Würbel, H. (2017) · Lab Animal · doi:10.1038/laban.1220 · Cited by 152
Human radiolabeled mass balance studies: objectives, utilities and limitations
Penner, N., Klunk, L. J., & Prakash, C. (2009) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.661 · Cited by 152
Sirenko, O., Cromwell, E. F., Crittenden, C., Wignall, J. A., Wright, F. A., & Rusyn, I. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.09.017 · Cited by 149
“…stem cell; calcium transient; ion channel; hERG; fast kinetic fluorescence imaging; screening Introduction Cardiotoxicity is a well-known side effect of many drugs and a leading cause of safetybased compound attrition in preclinical drug development (Kola and Landis, 2004; Laverty et al., 2011).”
Chan, T. S., Yu, H., Moore, A., Khetani, S. R., & Tweedie, D. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.053397 · Cited by 160
The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials
Marchetti, S., & Schellens, J. H. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603925 · Cited by 167
“It has been estimated that currently a novel compound entering clinical Phase I testing has only an 8% chance of reaching the market, and the probability is even lower for an anticancer drug (Food and Drug Administration, 2006, http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf; Kola and Landis, 2004).”
BackgroundDrug Promiscuity in PDB: Protein Binding Site Similarity Is Key
Haupt, V. J., Daminelli, S., & Schroeder, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065894 · Cited by 147
“However, the high attrition rates in late stage clinical trials due to a lack of efficacy [1] indicate that something is wrong with the ‘‘one drug – one target’’ paradigm.”
BackgroundComprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents
Lakshminarayana, S. B., Huat, T. B., Ho, P. C., Manjunatha, U. H., Dartois, V., Dick, T., & Rao, S. P. S. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku457 · Cited by 151
Ganter, B., Snyder, R. D., Halbert, D. N., & Lee, M. D. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.7.1025 · Cited by 147
Denton, K. R., Lei, L., Grenier, J. M., Rodionov, V., Blackstone, C. D., & Li, X.-J. (2014) · Stem Cells · doi:10.1002/stem.1569 · Cited by 162
In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review
Lambrinidis, G., Vallianatou, T., & Tsantili‐Kakoulidou, A. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.011 · Cited by 160
“In the beginning of the 21st century, statistics showed that the attrition rate rooted less on poor absorption but rather on drug efficacy and drug safety issues [7], both involving plasma protein binding (PPB).”
BackgroundMetabolic stability and its role in the discovery of new chemical entities
Słoczyńska, K., Gunia‐Krzyżak, A., Koczurkiewicz, P., Wójcik‐Pszczoła, K., Żelaszczyk, D., Popiół, J., & Pękala, E. (2019) · Acta Pharmaceutica · doi:10.2478/acph-2019-0024 · Cited by 158
Structure – ADME relationship: still a long way to go?
Hou, T., & Wang, J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.6.759 · Cited by 150
“Overall, the failure of developing candidates due to improper ADME/formulation, toxicology, and safety issues decreased from approximately 60% in 1991 to around 45% in 2000 [5] .”
Backgrounddel Val, I. J., Kontoravdi, C., & Nagy, J. M. (2010) · Biotechnology Progress · doi:10.1002/btpr.470 · Cited by 139
“%) as reported by Reichert5 and Kola and Landis.6 The aforementioned reports show the current relevance of mAbs and their potential for further development in the field of drug discovery.”
ResultNew Insights into Toxicity and Drug Testing
(2013) · InTech eBooks · doi:10.5772/55886 · Cited by 149
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Shih, H.-P., Zhang, X., & Aronov, A. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.194 · Cited by 160
Using Zebrafish for Investigating the Molecular Mechanisms of Drug-Induced Cardiotoxicity
Zakaria, Z. Z., Benslimane, F. M., Nasrallah, G. K., Shurbaji, S., Younes, N., Mraiche, F., Da'as, S. I., & Yalcin, H. C. (2018) · BioMed Research International · doi:10.1155/2018/1642684 · Cited by 166
Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery *
Blanco, E., Shen, H., & Mauro Ferrari, B. (2020) · doi:10.1201/9780429027819-9 · Cited by 149
Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?
Satalkar, P. P., Elger, B. S., & Shaw, D. (2015) · Science and Engineering Ethics · doi:10.1007/s11948-015-9705-6 · Cited by 143
Targeting the Wnt pathways for therapies
Blagodatski, A., Poteryaev, D., & Katanaev, V. L. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-28 · Cited by 141
“They are highly selective and have much longer half-lives than small molecules [49,50].”
BackgroundRoberts, P. J., Usary, J. E., Darr, D. B., Dillon, P. M., Pfefferle, A. D., Whittle, M. C., Duncan, J. S., Johnson, S. M., Combest, A. J., Jin, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0563 · Cited by 138
“Treatment only resumed when one of 2 conditions was met: (1) the primary tumor progressed by at least 2 mm in any direction by caliper measurement or (2) a secondary tumor became palpable.”
BackgroundMethodBhattaram, V. A., Booth, B. P., Ramchandani, R. P., Beasley, B. N., Wang, Y., Tandon, V., Duan, J. Z., Baweja, R. K., Marroum, P. J., Uppoor, R. S., et al. (2005) · The AAPS Journal · doi:10.1208/aapsj070351 · Cited by 147
Coimbra, J. T. S., Feghali, R., Ribeiro, R. P., Ramos, M. J., & Fernandes, P. A. (2021) · RSC Advances · doi:10.1039/d0ra09995c · Cited by 155
Opportunities for Use of Human iPS Cells in Predictive Toxicology
Anson, B. D., Kolaja, K. L., & Kamp, T. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.9 · Cited by 145
Agoram, B. M., Martin, S. W., & van der Graaf, P. H. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.002 · Cited by 146
Methods for Measuring, Enhancing, and Accounting for Medication Adherence in Clinical Trials
Vrijens, B., & Urquhart, J. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.59 · Cited by 139
Kell, D. B., Dobson, P. D., Bilsland, E., & Oliver, S. G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.11.008 · Cited by 154
Natural products and Pharma 2011: Strategic changes spur new opportunities
Carter, G. T. (2011) · Natural Product Reports · doi:10.1039/c1np00033k · Cited by 142
Speeding up the Evaluation of New Agents in Cancer
Parmar, M. K. B., Barthel, F. M. S., Sydes, M., Langley, R., Kaplan, R., Eisenhauer, E., Brady, M., James, N., Bookman, M. A., Swart, A.-M., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn267 · Cited by 148
Editorial: preclinical data reproducibility for R&D - the challenge for neuroscience
Steckler, T. (2015) · SpringerPlus · doi:10.1186/2193-1801-4-1 · Cited by 140
Ohtsuki, S., Uchida, Y., Kubo, Y., & Terasaki, T. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22612 · Cited by 149
On the origins of drug polypharmacology
Jalencas, X., & Mestres, J. (2013) · MedChemComm · doi:10.1039/c2md20242e · Cited by 138
Desai, B., Dixon, K., Farrant, E., Feng, Q., Gibson, K. R., van Hoorn, W. P., Mills, J., Morgan, T., Parry, D. M., Ramjee, M. K., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400099d · Cited by 139
Eldik, L. J. V., Thompson, W. L., Ranaivo, H. R., Behanna, H. A., & Watterson, D. M. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)82015-0 · Cited by 152
PubChem as a Source of Polypharmacology
Chen, B., Wild, D., & Guha, R. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci9001876 · Cited by 140
Of Mice and Men: Bridging the Translational Disconnect in CNS Drug Discovery
Geerts, H. (2009) · CNS Drugs · doi:10.2165/11310890-000000000-00000 · Cited by 152
“The success rate of new CNS drugs entering phase I clinical development is only around 8%,([1]) leading to huge losses of invested capital and resources.”
Hypoxia Inducible Factor Pathway Inhibitors as Anticancer Therapeutics
Burroughs, S. K., Kaluz, S., Wang, D., Wang, K., Van Meir, E. G., & Wang, B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.17 · Cited by 140
Thakkar, S., Li, T., Liu, Z., Wu, L., Roberts, R., & Tong, W. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.022 · Cited by 140
Multi-Organs-on-Chips: Towards Long-Term Biomedical Investigations
Zhao, Y., Kankala, R. K., Wang, S.-B., & Chen, A.-Z. (2019) · Molecules · doi:10.3390/molecules24040675 · Cited by 134
“The inaccurate prediction of the PK-PD profile of any drug can increase the failure rate of its development process [53,54].”
BackgroundYang, Y., Engkvist, O., Llinàs, A., & Chen, H. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201548z · Cited by 149
Strategic Approach to Fit-for-Purpose Biomarkers in Drug Development
Wagner, J. A. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094611 · Cited by 137
Ward, T. H., Cummings, J., Dean, E. J., Greystoke, A., Hou, J., Backen, A. C., Ranson, M., & Dive, C. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604519 · Cited by 139
“Nowhere is this more pertinent than in the complex arena of anticancer drug development, where the rate of compound attrition is high and success rates in the clinic are low (Kola and Landis, 2004).”
Backgroundvan Midwoud, P. M., Groothuis, G. M. M., Merema, M. T., & Verpoorte, E. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22516 · Cited by 135
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Wong, E. H. F., Yocca, F., Smith, M. A., & Lee, C.-M. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000866 · Cited by 134
“: +1 302 885 4709 Fax : +1 302 886 1584 Email : erik.wong@astrazeneca.com Downloaded from https://academic.oup.com/ijnp/article-abstract/13/9/1269/693860 by guest on 27 July 2018 therapeutic areas (Insel, 2008 ; Kola & Landis, 2004; Anon., 2010).”
Tsaioun, K. (2016) · ALTEX · doi:10.14573/altex.1610101 · Cited by 131
Next generation organoids for biomedical research and applications
Lou, Y., & Leung, A. W. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.10.005 · Cited by 144
“The main causes of attrition were lack of efficacy and safety, each contributing to approximately 30% of failures (Kola and Landis, 2004).”
BackgroundSmith, D. A., Artursson, P., Avdeef, A., Di, L., Ecker, G. F., Faller, B., Houston, J. B., Kansy, M., Kerns, E. H., Krämer, S. D., et al. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400713v · Cited by 154
New challenges in the use of nanomedicine in cancer therapy
Rasool, M., Malik, A., Waquar, S., Arooj, M., Zahid, S., Asif, M., Shaheen, S., Hussain, A., Ullah, H., & Gan, S. H. (2022) · Bioengineered · doi:10.1080/21655979.2021.2012907 · Cited by 153
“Nanotechnology plays a role in enhancing the efficient delivery of the anticancer drug to the affected tissues by increasing the efficacy and reducing the side effects [1].”
BackgroundThe use of in vivo zebrafish assays in drug toxicity screening
Eimon, P. M., & Rubinstein, A. L. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902882128 · Cited by 147
“Recent reviews indicate that anywhere from 20 to 50% of failures can be attributed to toxicity and clinical safety [4-6].”
BackgroundHartung, T. (2011) · ALTEX · doi:10.14573/altex.2011.2.083 · Cited by 132
“…et al., 2004; Bremer et al., 2007; Bulgheroni et al., 2009; Hartung, 2009a, 2010b; Hoffmann et al., 2005; Jírová et al., 2010; Knudsen et al., 2009; Kola and Landis, 2004; Martin et al., 2009a,b; Olson et al., 2000; Scott et al., 2010; Snyder and Green, 2001. altex_2011_2_083_093_FFT-Hartung.indd…”
Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery
Ewart, L., Dehne, E.-M., Fabre, K., Gibbs, S., Hickman, J., Hornberg, E., Ingelman-Sundberg, M., Jang, K.-J., Jones, D. R., Lauschke, V. M., et al. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052722 · Cited by 128
“Attrition of promising drug candidates as a consequence of unacceptable toxicity is a major barrier to drug research and development (R&D) productivity (1, 2).”
BackgroundBioinformatics in translational drug discovery
Wooller, S. K., Benstead-Hume, G., Chen, X., Ali, Y., & Pearl, F. M. G. (2017) · Bioscience Reports · doi:10.1042/bsr20160180 · Cited by 147
Predicting adverse side effects of drugs
Huang, L.-C., Wu, X., & Chen, J. Y. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-s5-s11 · Cited by 133
“Systematic and quantitative studies of adverse side effects have become increasingly important due to rising concerns about the cytotoxicity of drugs in development [1].”
BackgroundA 3D Fibrous Scaffold Inducing Tumoroids: A Platform for Anticancer Drug Development
Girard, Y. K., Wang, C., Ravi, S., Howell, M. C., Mallela, J., Alibrahim, M., Green, R., Hellermann, G., Mohapatra, S. S., & Mohapatra, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075345 · Cited by 134
“Currently, potential anticancer drugs entering clinical development have the highest level of attrition (95%)[1] of any drugs in spite of the huge amounts (,1 billion dollars per drug) spent on their development and testing.”
Background
Metadata
- Authors
- Kola, I., & Landis, J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kola, Ismail
- ORCID
- Landis, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-08
- Volume
- 3
- Issue
- 8
- Pages
- 711-716
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1895993106
- Cited by
- 4,167
- References
- 7
- Citations by year
- 2026: 121 · 2025: 129 · 2024: 126 · 2023: 159 · 2022: 165 · 2021: 188 · 2020: 179 · 2019: 203 · 2018: 183 · 2017: 194 · 2016: 256 · 2015: 294 · 2014: 279 · 2013: 307 · 2012: 300
- FWCI
- 199.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Keywords
- pharmaceutical industry, attrition rates, R&D productivity, drug development costs, health care cost containment, drug costs, R&D investment
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Humans, Pharmacokinetics, Drug Design, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.